ind application - Robuta Search

https://www.globenewswire.com/fr/news-release/2023/09/18/2744662/0/en/ContraFect-Announces-Submission-of-IND-Application-to-the-FDA-for-its-Development-Candidate-CF-370.html ContraFect Announces Submission of IND Application to the YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery... ind application announces submission https://www.biospace.com/dyne-therapeutics-announces-submission-of-ind-application-to-initiate-clinical-trial-of-dyne-251-for-duchenne-muscular-dystrophy Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251... Dec 2, 2021 - Dyne Therapeutics, Inc. (Nasdaq: DYN), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration... ind application https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-annual-reports IND Application Reporting: Annual Reports | FDA IND Application Reporting: Annual Reports ind application annual reports reporting fda https://www.globenewswire.com/news-release/2016/01/21/803661/0/en/Collegium-Announces-FDA-Acceptance-of-IND-Application-for-Abuse-Deterrent-Hydrocodone-DETERx.html Collegium Announces FDA Acceptance of IND Application for Second Clinical Candidate to Leverage DETERx Technology Platform... ind application collegium announces fda acceptance https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-information-amendments IND Application Reporting: Information Amendments | FDA ind application reporting information amendments fda https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application?ref=limestonepost.org Investigational New Drug (IND) Application | FDA Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs. investigational new drug ind application fda https://www.biospace.com/transcenta-announces-nmpa-acceptance-of-ind-application-of-its-anti-sclerostin-monoclonal-antibody-tst002 Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody... Jul 6, 2021 - Transcenta Holding Limited today announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002. ind application https://www.biospace.com/immune-pharma-announces-fda-acceptance-of-investigational-new-drug-ind-application-in-the-u-s-for-bertilimumab-for-the-treatment-of-bullous-pemphig Immune Pharma Announces FDA Acceptance Of Investigational New Drug (IND) Application In The U.S.... https://www.biospace.com/editas-medicine-announces-fda-clearance-of-investigational-new-drug-ind-application-for-edit-301-for-the-treatment-of-transfusion-dependent-beta-thalassemia Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301... Dec 20, 2021 - Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND...